NCT02355431 / 2015-001642-28: Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations |
|
|
| Withdrawn | 2 | 0 | US | Itacitinib, INCB039110, erlotinib, Tarceva®, placebo | Incyte Corporation | Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma) | 09/15 | 09/15 | | |
| Terminated | 2 | 9 | US | Itacitinib, INCB039110, docetaxel | Incyte Corporation | NSCLC (Non-small Cell Lung Carcinoma) | 02/16 | 04/16 | | |